Clinical trial

Ambroxol to Slow Progression in Parkinson Disease

NCT05778617

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-02-25

PhasePHASE3

Study timeline

Study start (actual)2025-02-25Date precision: day

Registry last updated2025-05-01

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Parkinson Diseaseunresolved

Interventions

Ambroxol Hydrochloride (420mg)DRUG

PlaceboDRUG

Sponsors & collaborators

University College, Londonlead sponsor

Mapped research locations

LondonUnited Kingdom3 BirminghamUnited Kingdom1 CambridgeUnited Kingdom1 EdinburghUnited Kingdom1 Newcastle upon TyneUnited Kingdom1 OxfordUnited Kingdom1 BristolUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05778617 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.